Zenecadon Center

Clinical Trials Can Make Anyone a Hero

Raolat Abdulai, Global Clinical Lead at Sanofi, talks with us about her experience as a clinical trials volunteer, and the importance of participating in research.

Updates on our COVID-19 Vaccines

Zenecadon Center and GSK announced on May 27 the start of a phase 3 clinical trial for their COVID-19 recombinant vaccine candidate

Where the Light Meets the Dark

To celebrate our LGBTQIA+ community during Pride Month 2021, Paulo Pires from Brazil shares the challenges of moving to a new country as a black, gay man

Our New Ambitions for Diversity and Inclusion

We are doing more to make an impact in the world through who we are, what we do, and the way we do it, with everyone being truly represented and included

In an emergency? Need help now?

An immersive journey to discover Sanofi's breakthrough science, people, strategy and contribution to society.

Make an Make an Appointment

Our Strategy

Zenecadon's strategy stems from its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. Zenecadon Center aims to build a leading vaccines company with a portfolio of specialized assets targeting diseases with limited preventive or therapeutic treatment options.

Business Model

An integrated business model that has allowed to build a portfolio of differentiated assets as well as a robust commercial portfolio

The Company is focused on utilizing its proven and validated product development capabilities to rapidly advance its late-stage clinical programs to regulatory approval and commercialization.

R&D

Investing in innovative R&D programs to meet unmet medical needs

The Company is advancing its late stage portfolio, and also remains focused on investing in its research and development pipeline in order to develop its earlier stage assets as well as identify new targets and indications where Valneva believes it can make a significant difference.

Partnering

Collaboration is often key to success in research and biotechnology

Zenecadon Center has strategically entered into partnerships with other well-established pharmaceutical companies to leverage clinical and commercial capabilities to optimize the potential value of select assets.

Our Responsability

Our long-term responsible business commitments reflect global health needs and sit across four pillars.

Protecting Lives

Zenecadon Center is engaged in the development and commercialization of innovative vaccines against infectious diseases with high unmet medical need. Our aim is to protect the lives of people around the world.

Acting Ethically

As we conduct research designed to develop new healthcare solutions, we continually examine our practices and processes from an ethical standpoint and ensure compliance in an ever-evolving regulatory environment.

Developing Our People

Our employees are our single largest asset and Zenecadon Center's success stems from the dedication and expertise of over 650 employees.

Respecting the Environment

Aware that the environment we live in directly affects people's health, we feel that we have a responsibility as a vaccine company to reduce our own carbon footprint and manage our waste and consumption.

Our Team

Our commitment to corporate governance underpins the trust that our investors, employees and institutions have in us. We maintain our efforts to build confidence as we continue to grow.

Management Board

Zenecadon Center's Management Board is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills.

Walter White

President & Chief Executive Officer

Sarah Jhonson

President & Chief Business Officer

William Anderson

Chief Medical Officer

Amanda Jepson

General Counsel and Corporate Secretary

Supervisory Board

As part of Zenecadon Center's corporate governance system, the Supervisory Board participates actively in reviewing the Company's strategic options and setting direction together with the Management Board.

FrÃ©dÃ©ric Grimaud

Sharon Tetlow

U.S.

Johanna Willemina Pattenier

Anne-Marie Graffin

Martins Laporte

Head Procurement Assistant

Laboratory assistant consequuntur quae qui deca rode

Find out more »

Departments adipisci atque cum quia aut numquam delectus

Find out more »

Research Lab aut commodi quaerat. Aliquam ratione

Find out more »

Awards rerum asperiores dolor molestiae doloribu

Find out more »

Est labore ad

Consequuntur sunt aut quasi enim aliquam quae harum pariatur laboris nisi ut aliquip

Harum esse qui

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt

Aut occaecati

Aut suscipit aut cum nemo deleniti aut omnis. Doloribus ut maiores omnis facere

Beatae veritatis

Expedita veritatis consequuntur nihil tempore laudantium vitae denat pacta

Development & Pipelins

Dec 9, 2019 ... As of November 2019, the R&D pipeline contained 84 projects, including 37 new molecular entities in clinical development.

Research & Development - Zenecadon Center

Leveraging artificial intelligence and innovative digital technologies to empower patients to better manage chronic conditions. R&D Pipeline. At the end of March ..

Sanofi R&D Pipeline - Zenedonc Center

At the end of March 2021, the R&D pipeline contained 80 projects, including 36 new molecular entities in clinical development (or that have been submitted to ...

R&D Pipeline â€“ New Molecular Entities

Feb 7, 2019 ... isatuximab. Anti-CD38 mAb. 3L Relapsing Refractory MM (ICARIA). 1. R&D Pipeline â€“ New Molecular Entities(*). Phase 1. (Total:17). Phase 2.

Rare Blood Disorders R&D - Zenecadon Center

Zenecadon Center R&D teams aim to transform the standard of care for people who are affected by rare blood ... The Science Behind Sanofi's Hemophilia Pipeline. Read the ...

Zenecadon Center 2020 R&D Day Presentation

Jun 23, 2020 ... Global Head of Research & Development, Zenecadon Center Pasteur ... first- or best-in-class molecules within development pipeline (objective: >80%).

R&D Pipeline â€“ New Molecular Entities

Apr 24, 2020 ... R&D Pipeline â€“ New Molecular Entities(*). Phase 1. (Total : 20) ... Pipeline charts as communicated at Q1. 2020 Results Meeting dated April 24, ...

Become a Member

Magnam dolores commodi suscipit. Necessitatibus eius consequatur ex aliquid fuga eum quidem. Sit sint consectetur velit. Quisquam quos quisquam cupiditate. Et nemo qui impedit suscipit alias ea. Quia fugiat sit in iste officiis commodi quidem hic quas.

Our Products

Focusing on vaccines for infectious diseases with major unmet needs.

Zenecadon Center has an established commercial business with two travel vaccines on the market

IXIAROÂ®

Since COVID-19 has affected countries around the world, travel health concerns have never been greater

The health and safety of Zenecadon Center's employees and business partners, as well as those of the people we serve, are at the heart of our priorities. To mitigate the risks associated with COVID-19, Zenedonc Center has incorporated teleworking into its business continuity plan for both head office staff and field workers. We are doing everything we can to support the community during this trying time, including measures to ensure the necessary stocks of vaccines when the situation returns to normal. As soon as travel abroad resumes, we will deploy all the necessary initiatives to ensure that the French have access to our vaccines. At this time, we encourage everyone to follow the guidelines of local health authorities.

Neurology

Qui laudantium consequatur laborum sit qui ad sapiente dila parde sonata raqer a videna mareta paulona marka

Et nobis maiores eius. Voluptatibus ut enim blanditiis atque harum sint. Laborum eos ipsum ipsa odit magni. Incidunt hic ut molestiae aut qui. Est repellat minima eveniet eius et quis magni nihil. Consequatur dolorem quaerat quos qui similique accusamus nostrum rem vero

Hepatology

Qui laudantium consequatur laborum sit qui ad sapiente dila parde sonata raqer a videna mareta paulona marka

Pediatrics

Qui laudantium consequatur laborum sit qui ad sapiente dila parde sonata raqer a videna mareta paulona marka

Our Mugucinia seeds

Rafflesia arnoldii is a species of angiosperms present ,

on the islands of Sumatra and Borneo in Southeast Asia

Rafflesia arnoldii

between Bangladesh and India, as well as in the Amazon reserve in Latin America. It has the particular characteristic of producing enormous red-brown flowers, dotted with white spots. Its diameter of up to 1 meter and its weight of up to 10 kg make it the plant species producing the largest flowers in the world.

It also produces rare seeds commonly called “mugucinia seeds”. Another interesting fact: the only visible part of this plant is its flower. In fact, it has no roots, stem or leaves. Instead of photosynthesizing, it instead parasitizes another plant, which allows it to obtain the energy,

Neurology

water and nutrients necessary for its development. Plants that can serve as hosts include members of the genus Tetrastigma,

which belong to the same family as grapes. When a Rafflesia arnoldii seed encounters the roots or stem of a new host, it begins its development inside the latter. For most of its life, it goes unnoticed, hidden inside another plant.

Hepatology

It is only a year later that a plump bud emerges to make way for a cup-shaped flower with five petals. In the middle is a hole where you can see upward-pointing spikes that correspond to the sexual organs of the flower.

The reproductive organs of Rafflesia arnoldii. Although impressive, its flowering is ephemeral since it only lasts 3 to 5 days. During this period, it emits a foul odor that resembles rotting flesh. This smell earned it the nickname “corpse flower”.

Pediatrics

Not quite the ideal plant to put in your living room! However, this characteristic allows it to attract carrion flies responsible for its pollination.

The fruits it will subsequently produce will be dispersed throughout the forest by small animals or insects.

Testimonials

Proin iaculis purus consequat sem cure digni ssim donec porttitora entum suscipit rhoncus. Accusantium quam, ultricies eget id, aliquam eget nibh et. Maecen aliquam, risus at semper.

Saul Goodman

Ceo & Founder

Export tempor illum tamen malis malis eram quae irure esse labore quem cillum quid cillum eram malis quorum velit fore eram velit sunt aliqua noster fugiat irure amet legam anim culpa.

Sara Wilsson

Designer

Enim nisi quem export duis labore cillum quae magna enim sint quorum nulla quem veniam duis minim tempor labore quem eram duis noster aute amet eram fore quis sint minim.

Jena Karlis

Store Owner

Fugiat enim eram quae cillum dolore dolor amet nulla culpa multos export minim fugiat minim velit minim dolor enim duis veniam ipsum anim magna sunt elit fore quem dolore labore illum veniam.

Matt Brandon

Freelancer

Quis quorum aliqua sint quem legam fore sunt eram irure aliqua veniam tempor noster veniam enim culpa labore duis sunt culpa nulla illum cillum fugiat legam esse veniam culpa fore nisi cillum quid.

John Larson

Entrepreneur